Related Experiment Video

Updated: Jun 23, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases

Amalia A Sofianidi1, Evangelia Panagodimou2, Emmanouil Kalampokas2

  • 1Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens School of Medicine, Vasilissis Sofias 76, Athens, 115 28, Greece. amaliasof@med.uoa.gr.

Current Oncology Reports
|June 22, 2026
PubMed
Abstract

Insights

Sacituzumab govitecan shows promise for gynecologic cancers. Ongoing trials in cervical, ovarian, and endometrial cancers are evaluating its efficacy and safety, with manageable toxicity observed.

Area of Science:

  • Gynecologic Oncology
  • Pharmacology
  • Oncology

Background:

  • Sacituzumab govitecan is an antibody-drug conjugate targeting TROP2.
  • TROP2 is highly expressed on various cancer cells.
  • It has shown efficacy in breast and lung cancers.

Purpose of the Study:

  • To review the therapeutic potential of Sacituzumab govitecan in gynecologic malignancies.
  • To summarize recent clinical evidence for its application in these cancers.

Main Methods:

  • Review of ongoing Phase III clinical trials.
  • Analysis of preliminary safety and efficacy data.

Main Results:

  • Ongoing trials include cervical, ovarian, and endometrial cancers.
  • Preliminary safety profile is manageable, with common toxicities like hematologic issues and alopecia.
  • Mature data on survival and response rates are pending.

Conclusions:

  • Sacituzumab govitecan demonstrates therapeutic potential in gynecologic cancers.
  • Biomarker analyses may improve patient selection and prognosis.
  • Further data from Phase III trials are crucial.
Keywords:
Antibody drug conjugatesCervicalEndometrialMK-2870OvarianSac-TMTSacituzumab tirumotecan

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...